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Abstract
Background: Huntington’s disease is caused by aggregation of mutant huntingtin (mHtt) protein containing more
than a 36 polyQ repeat. Upregulation of macroautophagy was suggested as a neuroprotective strategy to degrade
mutant huntingtin. However, macroautophagy initiation has been shown to be highly efficient in neurons whereas
lysosomal activities are rate limiting. The role of the lysosomal and other proteases in Huntington is not clear.
Some studies suggest that certain protease activities may contribute to toxicity whereas others are consistent with
protection. These discrepancies may be due to a number of mechanisms including distinct effects of the specific
intermediate digestion products of mutant huntingtin generated by different proteases. These observations
suggested a critical need to investigate the consequence of upregulation of individual lysosomal enzyme in
mutant huntingtin accumulation and toxicity.
Results: In this study, we used molecular approaches to enhance lysosomal protease activities and examined their
effects on mutant huntingtin level and toxicity. We found that enhanced expression of lysosomal cathepsins D and
B resulted in their increased enzymatic activities and reduced both full-length and fragmented huntingtin in
transfected HEK cells. Furthermore, enhanced expression of cathepsin D or B protected against mutant huntingtin
toxicity in primary neurons, and their neuroprotection is dependent on macroautophagy.
Conclusions: These observations demonstrate a neuroprotective effect of enhancing lysosomal cathepsins in
reducing mutant huntingtin level and toxicity in transfected cells. They highlight the potential importance of
neuroprotection mediated by cathepsin D or B through macroautophagy.
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Background
A common feature of neurodegenerative diseases,
including Alzheimer’s, Parkinson’s and Huntington’s dis-
eases, is the accumulation of aggregation-prone proteins,
such as b-amyloid in Alzheimer’s disease, a-synuclein in
Parkinson’s disease and mutant huntingtin (mHtt) in
Huntington’s disease [1]. It is generally thought that the
response of the neuronal cell to these aggregated pro-
teins determines whether cell death or dysfunction
occurs [1]. In this respect the autophagy-lysosomal path-
way is particularly important. Lysosomal-mediated
macroautophagy is largely responsible for degradation of
intracellular damaged or aggregated proteins. The
macroautophagy process involves formation of autopha-
gosomes, transportation of damaged or aggregated pro-
teins to the lysosomes, and degradation of these
proteins by lysosomal proteases. Because of this capabil-
ity for high capacity protein degradation inherent in
macroautophagy the pathway has been identified as a
potential target for the removal of mHtt protein. Pre-
vious studies have explored the potential of up-regulat-
ing autophagosomal formation by rapamycin, trehalose
and lithium, and this resulted in the decreased mHtt
aggregation and toxicity in vitro [2,3]. Recent studies in
the context of Alzheimer’s disease models have indi-
cated that macroautophagy is a highly efficient process
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any medium, provided the original work is properly cited.in neurons, and the activities of lysosomal proteins are
rate limiting in degrading aggregated proteins [4]. If
lysosomal activities are rate limiting, enhancing their
activities may alleviate the burden to the proteasomes
that are also involved in degradation of huntingtin [5,6].
Supporting this notion, dysfu n c t i o ni nt h el y s o s o m a l
pathway has long been implicated in aging and neurode-
generative diseases [7-17]. Thus, investigating the impact
of enhancing lysosomal proteins on mutant huntingtin
accumulation and toxicity is of particular importance.
Lysosomal proteases that are highly expressed in the
brain include the aspartate protease Cathepsin D
(CathD) and the cysteine protease (CathB) [7-17]. Loss
of cathepsins in processing damaged or aggregated pro-
teins has been demonstrated in neurological disorders as
well as mouse neurological disease models [7,18-20]. For
example, deficiency of CathB has been shown previously
to exacerbate Ab accumulation in a mouse model for
Alzheimer’s disease and overexpression of CathB has
been shown to reduce Ab load [18]. In addition, we and
others have previously shown that mice with deficient
lysosomal CathD exhibited significant a-synuclein accu-
mulation in their brains, indicating a critical role for
CathD in mediating a-synuclein metabolism [19,20].
This is important because a-synuclein mutation and
gene amplification is responsible for a small subset of
familial Parkinson’s disease cases, and a-synuclein is a
major component of Lewy bodies in a majority of spora-
dic Parkinson’s disease patients [21]. In vitro,w eh a v e
shown that overexpression of CathD decreases the level
of a-synuclein aggregation and protects against a-synu-
clein-mediated toxicity [19,20]. Similarly, in Parkinson’s
disease research, proteolytic reduction of aggregation-
prone and neurotoxic mutant huntingtin is important in
Huntington’s disease research. Because the huntingtin
gene is essential for development [22], the simple reduc-
tion of the huntingtin gene may not be ideal therapeutic
strategy. Allelic reduction of mutant huntingtin gene
can prevent further production of the product, but lacks
the potential to clear accumulated huntingtin toxic pro-
tein products. Determining which proteases are neuro-
protective and which are detrimental to neurons is
critically needed, considering the existence of protea-
somes and distinct families of proteases in the cell that
are capable of digesting mutant huntingtin to a varying
extent [5,6].
In the present study, we investigated whether enhan-
cing individual lysosomal proteases may be effective in
reducing mHtt using a range of molecular approaches.
Because full-length mHtt is produced in Huntington’s
d i s e a s ep a t i e n t sa n dm a yb em o r er e l e v a n tt on e u r o n
cell death mechanisms [23], we investigated the effects
of lysosomal enzymes on the toxicity of the full-length
mHtt in neurons. Our finding indicated that lysosomal
CathD and CathB reduced mHtt level, and protected
against mHtt toxicity in primary neurons. Furthermore,
CathD and CathB neuroprotective effects are dependent
on autophagy.
Methods
Reagents and antibodies
3-methyladenine (3-MA), pepstatin A (PepA) and E64d
were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Nucleofector Kit was from Lonza (Walkersville,
MD, USA). Lipofectamine 2000 was from Invitrogen.
Anti-huntingtin monoclonal antibody 2166 (Ab2166),
anti-polyglutamine expansion monoclonal antibody
MAB1574 (clone 1C2) and anti-huntingtin monoclonal
antibody (clone mEM48) were purchased from Millipore
(Temecula, CA, USA). Anti-cathepsin D and Anti-cathe-
psin B antibodies were obtained from Santa Cruz Bio-
technology (Santa Cruz, CA, USA). Anti-LAMP1 was
from Novus Biologicals (Littleton CO, USA). Anti-LC3
antibody was from Sigma-Aldrich (St. Louis, MO, USA).
Anti-b-actin monoclonal antibody was from Sigma-
Aldrich. Fluorescent Alexa 488 (anti-mouse), fluorescent
Alexa 568 (anti-goat) and fluorescent Alexa 488 (anti-
rabbit) secondary antibodies were from Invitrogen
(Carlsbad, CA, USA). Horseradish peroxidase-labeled
secondary antibodies for enhanced chemiluminescence
system detection were from Pierce (Rockford, IL USA).
Plasmids
Full-length Htt with 23 or 145 polyQ repeats using
pcDNA vector were purchased from Invitrogen. Plas-
mids encoding human cathepsin D and B in pCMV-5a
expression vectors were purchased from Origene.
HEK293 cell culture and transfection
HEK293 cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) (Invitrogen) supplemented with
10% fetal bovine serum (FBS) (Atlanta Biologicals), and
100 U/ml penicillin/streptomycin (Invitrogen) at 37°C, and
5% CO2. Transfections were performed using lipofecta-
mine 2000 according to the manufacturer’s instructions.
Cell death was measured by trypan blue exclusion, MTS
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphe-
nyl)-2-(4-sulfophenyl)-2H-tetrazolium) colorimetric and
Calcein AM viability assays.
Primary neuron cultures and transfection
The animal studies have been approved by the Univer-
sity of Alabama at Birmingham IACUC. Primary cortical
neurons were obtained from embryonic day 18 (E18)
embryos. Timed-pregnant Sprague-Dawley rats (Charles
River Laboratories, Wilmington, MA, USA) were sacri-
ficed by CO2 inhalation and embryos were collected in a
Petri dish and placed on ice. Dissections were performed
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2+
and Mg
2+). Cerebral cortices were isolated and collected
in a 15 ml Falcon tube. The tissues were incubated for
15 min at 37°C with papain (Worthington). The tissues
were mechanically dissociated with a fire-polished Pas-
teur pipette. Cells were finally concentrated by centrifu-
gation at 25°C for 5 min at 1000 × g and resuspended
in Neurobasal medium containing 2% B27 supplement
(Invitrogen), 1% Pen-Strep (10,000 U/ml, 10,000 μg/ml)
and 0.5 mM L-glutamine. Electroporation was per-
formed using Rat Nucleofector Kit with Nucleofector II
machine. Cells were then plated in multiwell 24-well or
6-well plates coated with 0.1 mg/ml Poly-L-Lysine
(Sigma). The cultures were kept in a humid incubator
(5% CO2,3 7 ° C )a n dh a l fo ft h em e d i u mw a sc h a n g e d
once a week.
Immunocytochemistry
Cells on coverslips were washed by room temperature
PBS and fixed in 4% paraformaldehyde for 45 min. After
washing with PBS, the fixed cells were then permeabi-
lized with PBS-T (0.1% Triton X-100 in PBS) for 3 min.
The cells on coverslips were blocked in PBS supplemen-
ted with 3% BSA for 1 hour at room temperature. The
cells were then incubated with a primary antibody in
blocking solution overnight at 4°C and then washed 3
times with PBS. The secondary antibody conjugated to
fluorophores was incubated for 1 hr at room tempera-
ture. Before mounting in fluoromount G on microscope
slides, coverslips were incubated in 2 μg/ml Hoechst
33342 to label nuclear DNA. Stained cells were visua-
lized by a fluorescent microscope (Leica Microsystems,
Wetzlar, Germany). Staining was visualized on a Zeiss
Axiocam CCD camera on a 100 W Axioscope bright
field and fluorescence microscope.
Measurement of neuronal death
For the cell death assay, primary cortical neurons were
electroporated the day of plating with the rat neuron
nucleofector kit (Lonza) and then plated in 24-well
plates with coverslips. At 9 DIV (day in vitro), cells were
fixed and immunostained with mAb2166 antibody as
above, and nuclei counter-stained by Hoechst to identify
degenerated neurons by counting mAb2166-positive
neurons with nuclei shrinkage or fragmentation. We
selected 15-20 random fields for each coverslip to take
images for quantifying cell death. Each graph represents
three independent experiments. Data are expressed as
the percentage of neuronal cell death.
Western blot analysis
Total cellular extracts were collected in lysis buffer con-
taining 50 mM Tris-HCl pH7.4, 150 mM NaCl, 5 mM
EDTA, 1% Triton X-100 and supplemented with protease
inhibitor mixture (Roche). Homogenates were centri-
fuged at 10,000 × g for 15 min at 4°C. Protein concentra-
tions were determined by detergent-compatible protein
assay (Bio-Rad). Protein extracts were mixed with 5 ×
sample loading buffer and boiled for 5 min. Thirty to fifty
micrograms of protein was resolved on 12% SDS-PAGE
gel and transferred to nitrocellulose membranes. Mem-
branes were blocked in 5% non-fat dry milk or 5% horse
serum (for cathepsin D antibody detection) in TBST
(50 mM Tris-HCl, 150 mM NaCl, pH7.4, 0.1% Tween
20) for 30 min at room temperature. The membranes
were then incubated overnight at 4°C with primary anti-
bodies: anti-mAb2166 1:1000; anti-1C2 1:5000; anti-
EM48 1:1000; anti-cathepsin D 1:1000; anti-cathepsin B
1:1000; anti-LC3 1:1000 or anti-actin 1:5000. The
membranes were then washed 4 times with TBST and
incubated with horseradish peroxidase-conjugated sec-
ondary antibody for 1 h at room temperature. After
washing for 40 min with TBST, the membranes were
developed using enhanced chemiluminescence (ECL)
substrate kit. We used U-Scan-IT software to quantify
the western blot band intensity.
CathD and CathB activity assay
CathD activity was measured using an assay kit from
Sigma. Cells were lysed in 20 mM MES pH6.8 contain-
ing 80 mM NaCl, 1 mM MgCl2,2m ME G T A ,1 0m M
NaH2PO4, proteinase inhibitor cocktail and phosphotase
inhibitor cocktail. Ten μg of cell lysate were assayed in a
96-well plate according to protocol described by the
manufacturer. CathB activity was measured using a kit
from Biovision. Cells were lysed with the cell lysis buffer
supplied with the kit. CathB activity was measured in a
96-well plate according to manufacturer’s instruction.
Real-time RT-PCR
Total RNA was extracted using TRIZOL reagent from
Invitrogen. cDNA was synthesized using an iScript
cDNA synthesis kit(BioRad) following the manufac-
turer’s instructions.
Real-time PCR was performed to determine the mRNA
levels of Htt and CathD and CathB. Primer sequences
w e r e :G A P D H ,5 ’- GCCAAAAGGGTCATCATCTC-3’
and 5’GGCCATCCACAGTCTTCT-3’;C a t h D ,5 ’-TTC
CCGAGGTGCTCAAGAACTACA -3’and 5’-TGTCGAA-
GACGACTGTGAAGCACT -3’;C a t h B ,5 ’-AAGCTTC-
GATGCACGGGAACAA-3’ and 5’-ATGCAGATCCGG
TCAGAGAT-3’.
Htt, 5’- CTCATTTCTCCGTCAGCACA-3’ and 5’-
CAAAGCTTCACAGCATCCAA-3’.
The mRNA level of GAPDH served as an internal
control.
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Data are reported as means ± SEM. Comparisons
between two groups were performed with unpaired Stu-
dent’s t-tests. Comparisons among multiple groups or
between two groups at multiple time-points were per-
formed by either one-way or two-way analysis of var-
iance, as appropriate. A p v a l u eo fl e s st h a n0 . 0 5w a s
considered statistically significant.
Results
Overexpression of cathepsins D (CathD) and B (CathB)
reduce mHtt level in human embryonic kidney (HEK) cells
Consistent with prior studies [24], we found that over-
expressing full-length Htt protein with a short polyQ
repeat (23QHtt) or mHtt protein with a long polyQ
repeat (145QmHtt) did not induce cell death assessed
by three independent methods (Calcein AM, MTS (3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium) colorimetric cell sur-
vival, or trypan blue exclusion assays). Cells transfected
with full-length 23QHtt and 145QmHtt were used to
investigate whether enhancing lysosomal cathepsin
level can reduce Htt or mHtt protein levels. For this
purpose, we co-transfected HEK cells with plasmids
encoding lysosomal CathD or CathB, together with
plasmids encoding full-length Htt or mHtt proteins.
Western blot analyses show that the expression of
both cathepsin precursors and mature proteins are sig-
nificantly increased 8-25 fold, regardless of whether
the cells contained 23QHtt or 145QmHtt (Figure 1A).
These data indicate that mHtt did not affect CathD or
C a t h Bp r o c e s s i n gt ot h em a t u r ef o r m s .B yw e s t e r nb l o t
analyses, we found no significant compensation or
cross regulation of CathB as a consequence of overex-
pressing CathD and vice versa (Additional file 1, Figure
S1A). Real-time RT-PCR results showed that the
mRNA levels of CathD or CathB are greatly increased
in CathD or CathB transfected cells with or without
23QHtt or 145QmHtt (Additional file 1, Figure S1B).
In addition to the increases of CathD or CathB protein
and mRNA levels, we found significant increase of
enzymatic activities in CathD or CathB transfected
cells with or without 23QHtt or 145QmHtt (Figure
1B). CathD or CathB overexpression did not cause an
off-target degradation of proteins, as indicated by wes-
tern blot analyses of mitochondrial outer membrane
protein VDAC and endoplasmic reticulum protein cal-
nexin (Additional file 1, Figure S1C). To determine
how overexpression of cathepsins affect the total level
and cleaved Htt, we performed western blot analyses
using 1C2 antibody that is specific for the polyQ of
145QmHtt (Figure 1C), EM48 that preferentially recog-
nizes the aggregates (Figure 1D) and Ab2166 that
recognizes both Htt and mHtt (Figure 1E). We found
that CathD and CathB significantly reduced both full-
length and cleaved forms of Htt and mHtt as detected
by all 3 antibodies (Figure 1C-1E). The species of
23QHtt and 145QmHtt recognized by these antibodies
are similarly decreased by CathB and CathD. Endogen-
ous Htt levels are not significantly decreased by CathD
or CathB transfection (Additional file 1, Figure S1D),
suggesting that CathD or CathB has more effect on
decreasing excessive exogenous htt levels. The RNA
levels of Htt were not affected by CathD or CathB
transfection as shown by quantitative RT-PCR (Addi-
tional file 1, Figure S1E), suggesting that all the trans-
fections had similar transfection efficiency.
Cathepsin D (CathD) and B (CathB) inhibitors exacerbate
mHtt toxicity in primary neurons
Huntington’s disease patients exhibit neurodegeneration
in both cortex and striatum [25]. Because we did not
find a significant increase of cell death after 145QmHtt
transfection compared to 23QHtt transfection in HEK
cells, we investigated the effects of 145QmHtt versus
23QHtt on cell death in primary cortical neurons. We
harvested primary cortical neurons from embryonic day
18 rats, transfected with full-length 23QHtt and
145QmHtt, and cultured in vitro for 9 days (9 DIV).
Transfection efficiency was consistently ~30% of all neu-
rons, as detected both by transfection with control plas-
mid encoding GFP protein, and by co-transfection of
GFP and 23QHtt or 145QmHtt constructs. We also
stained the cells with Ab2166 which recognizes both
2 3 Q H t ta n d1 4 5 Q m H t tp r o t e i n s ,a n dc o n f i r m e dt h e
transfection efficiencies with these plasmids encoding
23QHtt or 145QmHtt. To determine mHtt-induced cell
death, we stained the neuron cultures with Ab2166 anti-
body and counter-stained with Hoechst for nuclei.
Dying neurons exhibited nuclei with a pyknotic mor-
phology (Figure 2A). We found that 145QmHtt induced
significantly more cell death than 23QHtt in these neu-
rons (Figure 2B). To study the effects of inhibiting the
lysosomal pathway on 145QmHtt-induced cell death, we
treated the 23QHtt and the 145QmHtt-transfected neu-
rons with CathD and B inhibitors, pepstatin A (pepA)
and E64d, respectively. We found that these inhibitors
exacerbated 145QmHtt-induced neuronal cell death. In
addition, the PI3K inhibitor 3-MA, which inhibits autop-
hagosomal formation, increased toxicity to a similar
extent as that of the cathepsin inhibitors in the presence
of 145QmHtt, whereas it had no effect on cell death in
t h ep r e s e n c eo f2 3 Q H t t( F i g u r e2 B ) .T h ec o m b i n e du s e
of pepA and E64d further exacerbated 145Q-mHtt-
induced neuron death compared to either inhibitor
alone (Figure 2B).
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Page 4 of 12Figure 1 Cathepsin D (CathD) and B (CathB) reduce Htt loads in HEK cells. HEK cells transfected by lipofectamine with different Htt and
cathepsin cDNA constructs were harvested 48 hr later for real-time quantitative RT-PCR, western blot and enzymatic activity analyses. A.
Transfection of cathepsin D (CathD) and B (CathB) increases their expression in HEK cells. HEK cells were transfected with 23QHtt, 23QHtt plus
CathD, 23QHtt plus CathB, 145QmHtt, 145QmHtt plus CathD, and 145QmHtt plus CathB constructs for 48 hr. Western blot analyses were
performed with anti-CathD and anti-CathB antibodies. b-actin western blots were used as loading controls. Pre-pro forms of CathD are 49 and
50 kD. Mature CathD is 32 kD. Mature CathB is 27 kD. Relative expression levels were quantified by band intensity. Student t-test was performed.
*p < 0.05 compared to without cathepsin transfection. B. Increase of CathD and CathB enzymatic activities after transfection. HEK cells were
transfected with CathD and CathB, and as described in A. CathD and CathB activities were assayed by CathD or CathB activity assay kit. *p < 0.05
compared to without cathepsin transfection. (C-E) Transfection of CathD and CathB reduce transfected Htt levels. HEK cells were transfected
with 23QHtt, 23QHtt plus CathD, 23QHtt plus CathB, 145QmHtt, 145QmHtt plus CathD, and 145QmHtt plus CathB constructs. Western blot
analyses were performed first with (C) 1C2 antibody that is specific for the polyQ of 145QmHtt, and then with (D) EM48 that preferentially
recognizes the aggregates or (E) Ab2166 antibody that recognizes both 23Q and 145QHtt. b-actin western blots were used as loading controls.
*p < 0.05 compared to without cathepsin transfection. †p < 0.05 compared to 23Q transfection.
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Page 5 of 12Figure 2 Cathepsin D (CathD) and B (CathB) inhibitors exacerbate 145QmHtt-induced cell death in cortical neurons. A. 145QmHtt
transfected neurons exhibited increased cell death. Primary cortical neurons were transfected with 23QHtt and 145QmHtt constructs. At 9 DIV,
neurons were immunostained by anti-Htt Ab2166 and nuclei were stained by Hoechst. Arrows point to the pyknotic nuclei. Scale bar = 10
micron. B. 3-MA, pepstatin A and E64d exacerbated 145QmHtt-induced neuron death. The combined use of pepA and E64d further exacerbated
145Q-mhtt-induced neuron death. Primary cortical neurons (9 DIV) were treated with 3-MA (10mM), CathD and B inhibitors, pepstatin A (15 μM)
and E64d (30 μM), respectively, for 24 hr. Con = empty vector control. Neuronal cell death was scored by counting pyknotic nuclei after Hoescht
staining. There is no statistic significant difference in 23QHtt transfected neurons in the absence or presence of any of the chemicals. *p < 0.05
Student t-test compared to no inhibitor. †p < 0.05 compared to 23Q transfection. **p < 0.05 Student t-test compared to either pepA or E64d
alone.
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neurotoxicity in primary neurons
We next examined whether increasing lysosomal activ-
ities reduces mHtt toxicity in primary cortical neurons.
With ~30% transfection efficiency, we found that the
protein expression levels of CathD and CathB are
increased by transfection of plasmids encoding CathD
and CathB, in primary cortical neurons (Figure 3A).
Quantification of the western blots indicated that the
increase of CathD and CathB are between 0.5 and 5 fold
(Figure 3A). Real-time PCR results showed that mRNA
levels of CathD or CathB are greatly increased in CathD
or CathB transfected cells with or without 23QHtt or
145QmHtt (Additional file 2, Figure S2). In addition to
increases in CathD or CathB protein and mRNA levels,
we found significant increase of enzymatic activities in
CathD or CathB transfected cells with or without
23QHtt or 145QmHtt (Figure 3B). We found that all
the CathD and CathB colocalized to the lysosomes, as
indicated by the co-immunostaining of CathD or CathB
with LAMP1 (Figure 3C and 3D).
Under these conditions, we found that 145QmHtt is
significantly more toxic than 23QHtt (Figure 4A), and
that 145QmHtt toxicity was reduced by co-transfection
with either CathD or CathB (Figure 4A). To determine
whether CathD and CathB neuroprotection against
mHtt toxicity is through an autophagy-mediated
mechanism, we investigated whether blockade of autop-
hagy reduces the neuroprotective effects of CathD and
CathB against 145QmHtt toxicity in primary cortical
neurons. We used 3-MA as an inhibitor for the autop-
hagy pathway. In 23QHtt transfected neurons, overex-
pression of CathD or CathB, or 3-MA inhibition alone
did not cause neuron death. However, in these 23QHtt
transfected neurons when autophagy is blocked by 3-
MA, increasing CathD or CathB increased cell death
(Figure 4B). In 145QmHtt transfected neurons, CathD
and CathB reduced 145QmHtt-induced neuron death
(Figure 4B). When autophagy is blocked by 3-MA,
145QmHtt is more toxic, and CathD or CathB
enhancement could no longer reduce 145QmHtt-
induced cell death (Figure 4B). Consistent with prior
studies in mHtt knock-in mice that autophagic stress
is induced by mHtt [26], we found that the ratio of
LC3 II/LC3 I was increased significantly in 145QmHtt
transfected neurons compared to 23QHtt transfected
neurons (Figure 4C). Western blot analyses showed
that in both 23QHtt and 145QmHtt transfected neu-
rons, co-transfection of either CathD or CathB chan-
ged the LC3II/LC3 I ratio, suggesting that CathD and
CathB changes the autophagy dynamics in response to
the overexpression of either wildtype or mutant Htt
protein (Figure 4C). In the absence of Htt, CathD or
CathB did not significantly change the ratio of LC3 II/
LC3 I (Additional file 1, Figure S3).
Discussion
Understanding the mechanisms of clearance of toxic
mutant huntingtin is essential in order to explore thera-
peutic strategies against Huntington’s disease. Here we
examined the role of enhancing lysosomal CathB or D
regarding the consequence of whether they are detri-
mental or protective against mutant huntingtin toxicity.
We found that overexpression of full-length Htt with 23
polyQ (23QHtt) and mHtt with 145 polyQ (145QmHtt)
had no effects on cell viability in HEK cells. This
allowed an assessment of the ability of CathB and D to
process huntingtin protein in the absence of the con-
founding effects of cell death. Prior studies indicated
that CathD is more effective in reducing a-synuclein
levels than CathB [19,20]. Interestingly, in our studies,
both proteases were capable of processing mHtt to an
equivalent extent. This may be due to the much bigger
size of the mHtt protein that allows for more proteolytic
cleavage sites compared to a-synuclein. It is interesting
to note that endogenous htt levels are not significantly
decreased by CathD or CathB transfection. Prior studies
demonstrated that endogenous normal htt plays an
important role in development [22], although its exact
role in neurons has not been well-established. Our
observation that increased CathD and CathB only
reduce excessive htt, without affecting basal level endo-
genous htt, is most likely because only in the case of
overproduction of htt is the lysosomal system engaged
for clearance of this protein. This would be consistent
with a potential benefit of increasing these lysosomal
activities for reduction of toxic proteins without redu-
cing endogenous functional proteins. mHtt can be
digested by proteasomes, caspases, cathepsins and
gamma-secretase in a variety of cell models [5,6,27-29].
For example, inhibiting proteasomes by inhibitors such
as ALLN and lactacystin was shown to promote the
accumulation of NH2-terminal Htt fragments in both
HEK293 cells and in brain tissues. Moreover, the endo-
genous NH2-terminal mutant Htt fragments accumu-
lated in the brains by proteasome inhibition [5,6,27-29].
The Autophagy-lysosome pathway is a key clearance
pathway for mHtt fragments. Induction of autophagy
protects against polyglutamine toxicity and inhibition of
autophagy has the converse effects [5,6,27-29]. Our
observations indicate that in vitro,u p - r e g u l a t i o no f
CathD or CathB does not lead to increased smaller
mHtt fragments, but reduced overall full length and
smaller fragments, consistent with a function of the
lysosomal enzymes in complete rather than partial
degradation of mHtt.
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Page 7 of 12Figure 3 Cathepsin D (CathD) and B (CathB) expression and localization in primary neurons. A. Western blot analyses of CathD and CathB
protein levels after transfection. Primary cortical neurons were transfected with 23QHtt, 23QHtt plus CathD, 23QHtt plus CathB, 145QmHtt,
145QmHtt plus CathD and 145QmHtt plus CathB constructs. Western blot analyses were performed with anti-CathD and anti-CathB antibodies.
b-actin western blots were used as loading controls. Relative expression levels were quantified by band intensity. Positions of molecular weight
markers were indicated. Quantification of the western blots are shown in the bar graphs. *p < 0.05 compared to without cathepsin transfection.
B. Analyses of CathD and CathB enzymatic activities after transfection. Primary cortical neurons were transfected with CathD, CathB and as
described in A. CathD and CathB activities were assayed by CathD or CathB activity assay kit. *p < 0.05 compared to without cathepsin
transfection. C and D. Colocalization of transfected CathD (C) and CathB (D) with LAMP-1. CathD and CathB transfected neurons were examined
by co-immunostaining of LAMP-1 and CathD or CathB. Yellow colored cytoplasmic spots are indicative of co-localization of transfected
cathepsins and LAMP-1. Scale bar = 10 micron.
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Page 8 of 12Figure 4 Cathepsin D (CathD) and B (CathB) reduce mHtt-induced toxicity in primary cortical neurons. A. Neurons were transfected with
full length 23QHtt or 145QmHtt, either alone or co-transfected with CathD or CathB. Con = empty vector control. Cell death was increased by
145QmHtt and reduced by co-transfection with CathD or CathB. *p < 0.05 compared between 145QmHtt alone versus 145QmHtt co-transfection
with CathD or CathB. †p < 0.05 compared between 145QmHtt and 23QHtt transfected cells. B. Blockade of autophagy reduces the effects of
CathD and CathB in neuroprotection against 145QmHtt induced cortical neuron death. In 23QHtt transfected neurons, overexpression of CathD
or CathB, or 3-MA inhibition alone did not cause neuron death. However, in these 23QHtt transfected neurons when autophagy is blocked by 3-
MA, increasing CathD or CathB increased cell death. In 145QmHtt transfected neurons, CathD and CathB reduced 145QmHtt-induced neuron
death. When autophagy is blocked by 3-MA, 145QmHtt is more toxic, and CathD or CathB enhancement could no longer reduce 145QmHtt-
induced cell death. Con = empty vector control. †p < 0.05 compared between 23QHtt transfected versus 145QmHtt transfected cells. *p < 0.05
compared between 145Q and 145Q+CathD or CathB transfected cells. #p < 0.05 compared between transfected cells with 3-MA treatment and
without 3-MA treatment. C. 145QmHtt increases LC3 II/LC3 I ratio. Primary neurons were transfected with 23QHtt, 23QHtt plus CathD, 23QHtt
plus CathB, 145QmHtt, 145QmHtt plus CathD, and 145QmHtt plus CathB constructs. Western blot analyses were performed with an anti-LC3
antibody. b-actin western blots were used as loading controls. Immunoreactive bands were quantified and shown in the graphs. *p < 0.05
compared between 145QmHtt and 23QHtt transfection.
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Page 9 of 12mHtt was shown to affect protein levels and matura-
tion of CathD in optineurin/Rab8-dependent trafficking
pathway from post-Golgi to lysosomes [30]. However, in
our studies, CathD and CathB mature enzymes are pro-
duced both in the absence and presence of mHtt. And
the CathD and CathB enzymatic activities are similar in
the absence and presence of mHtt. Furthermore, exo-
genously expressed CathD and CathB are localized to
the lysosomes. There could be a number of reasons for
these differences between ours and the prior studies,
including: a) different cells and constructs for the
expression of mHtt; and b) overexpressed CathD and
CathB in our studies reduced the levels of mHtt below
the levels needed to block protein trafficking.
145QmHtt over-expression in primary cortical neu-
rons resulted in increased cytotoxicity which was further
enhanced by the inhibitors of cathepsin B and D. 3-
methyladenine (3-MA), which inhibits autophagosome
formation due to its inhibitory effects on the VPS34-
Beclin complex, had a similar effect on mHtt toxicity as
the cathepsin inhibitors. The fact that the combined
effects of cathepsin B and D inhibition were greater
than either alone and similar to 3-MA suggest that both
proteases make a significant contribution to mHtt
degradation.
Prior studies have analyzed mTOR-dependent and
independent pathways in stimulating macroautophagy
[31]. Enhancing macroautoph a g ym a yb eb e n e f i c i a lt o
degradation of mHtt aggregates [2,3,31-34]. Rapamycin
induces autophagosome formation and reduces mHtt
aggregates, albeit this appears to be a somewhat ineffi-
cient process [32]. One explanation is that autophagoso-
mal activity is efficient in healthy neurons, such that
accumulation of autophagosomes is a rare event [4]. In
contrast, lysosomal protease activities seem to be rate-
limiting and easily disturbed as evidenced in a variety of
lysosomal diseases [4], and their activities decline with
age [10,24,35]. Recent studies also demonstrated that
up-regulation of lysosomal biogenesis reduced mHtt
levels in cell lines [36], highlighting the importance of
the lysosomes. Surprisingly, we did not observe LC3 II/
LC3 I conversion increase in CathD and CathB trans-
fected neurons, one explanation may be the autophagy
flux is too fast to measure LC3 II accumulation in
CathD and CathB transfected neurons. Interestingly, our
studies also observed that LC3 II/LC3 I ratio is upregu-
lated in primary neuron cultures transfected with CathD
and CathB in the presence of 23QHtt. This observation
suggests a feedback regulation by signals from the lyso-
some to the machinery regulating autophagosomal for-
mation. Recent studies suggest that mTOR may be in a
complex on the lysosomal membrane and can serve as a
signal for autophagy initiation [37]. Future studies will
critically investigate how lysosomal activities influence
autophagy initiation through either an mTOR-depen-
dent or an mTOR-independent pathway. In the
HdhQ200 knock-in mouse model, mHtt aggregates
colocalize with LC3 positive staining, suggesting accu-
mulation of mHtt within uncleared autophagosomes
[26]. Consisting with this observation, our studies also
showed 145QmHtt transfected neurons had increased
LC3 II/LC3 I ratio compared to 23QHtt transfected neu-
rons. CathD or CathB transfected neurons that express
145QmHtt exhibit reduced LC3 II/LC3 I ratio, suggesting
CathD and CathB play a role in helping clear the accu-
mulated autophagosomes in these neurons. Future stu-
dies will also need to critically investigate whether CathD
and CathB can serve not only to attenuate nascent mHtt
aggregate formation, but also to enhance clearance of
existing pre-formed aggregates [38].
Conclusions
This study demonstrates that enhanced activity of the
individual lysosomal proteases CathD or CathB, reduced
145Q mutant huntingtin level and toxicity in multiple
cell models. Neuroprotection by CathD or B is asso-
ciated with changes and dependent on the macroauto-
phagy pathway. The proposed model for CathD and B
neuroprotection against mHtt accumulation and toxicity
is shown in Figure 5. These observations lay a founda-
tion for further investigating molecular and cellular
mechanisms of autophagy-lysosomal regulation and
Figure 5 A model for neuroprotective effects of lysosomal
cathepsins D and B against mHtt toxicity. A. In Huntington’s
disease conditions, mHtt cannot be completely degraded and
accumulates, leading to neurotoxicity. 3-MA inhibits autophagy
activity and exacerbates mHtt-induced neurotoxicity. B. Increasing
lysosomal cathepsins D and B reduces mHtt accumulation, and
confers neuroprotection. Neuroprotection is dependent on
autophagy, since 3-MA reduces cells survival even in the presence
of CathD or B.
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Page 10 of 12therapeutic potential of enhancing lysosomal cathepsins
in reducing mutant huntingtin accumulation and
toxicity.
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